Jump to main content
Jump to site search

Issue 26, 2018
Previous Article Next Article

Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance

Author affiliations

Abstract

A key challenge of chemotherapy in clinical treatments is multidrug resistance (MDR), which mainly arises from drug efflux-induced tumor cell survival. Thus, it is necessary to provide biocompatible chemotherapeutics to improve drug accumulation in MDR cells. Herein, two clinical small molecular drugs, celastrol (CST) and doxorubicin (DOX), were self-assembled into carrier-free and biocompatible nanoparticles (CST/DOX NPs) via a simple and green precipitation method for synergistic combination chemotherapy to overcome DOX resistance. These spherical CST/DOX NPs can improve the water-solubility of CST, reduce the dosage of DOX, and therefore significantly enhance cellular drug accumulation by activating heat shock factor 1 (HSF-1) and inhibiting NF-κB to depress P-gp expression, which results in apoptosis and autophagy of DOX resistant cells through the ROS/JNK signaling pathway. Finally, synergistic combination chemotherapy was attained in both MCF-7/MDR cells and 3D multicellular tumor spheroids. Thus, CST/DOX NPs provide an alternative for overcoming drug resistance in future clinical applications.

Graphical abstract: Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance

Back to tab navigation

Supplementary files

Article information


Submitted
03 Apr 2018
Accepted
12 Jun 2018
First published
12 Jun 2018

Nanoscale, 2018,10, 12639-12649
Article type
Paper

Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance

Y. Xiao, J. Liu, M. Guo, H. Zhou, J. Jin, J. Liu, Y. Liu, Z. Zhang and C. Chen, Nanoscale, 2018, 10, 12639
DOI: 10.1039/C8NR02700E

Social activity

Search articles by author

Spotlight

Advertisements